HTA & Market Access (Roberto Ravasio)

All Items

• Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy

  Roberto Ravasio, Raffaella Viti, Antonio Saverio Roscini

  13-21

• Model for estimating the impact of healthcare costs in non-hospitalized Covid-19 patients treated with remdesivir

  Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Marco Falcone, Giovanni Di Perri

  114-121

• Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

  Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri

  105-111

• Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor

  Roberto Ravasio, Holly Cranmer, Izzie Kearns , Raffaella Viti, Simone Corinti

  92-104

• Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient

  Dunia Castillo-Gonzàles, Irianys Álvarez Sardiñas, Consuelo Macías Abraham, Alex G. Muñoz Bedoya

  83-86

• Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy

  Federica Demma, Pierpaola Arpa

  36-42

• Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions

  Roberto Ravasio, Paola Raimondo

  99-105

• Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy

  Gian Luca Breschi, Federica Demma, Paolo Morelli, Maria De Francesco

  81-87

• Orthopaedic device manufacturers’ perspective on MDR compliance

  Peter Fennema, Hassan Achakri

  34

• Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy Analisi di costo-efficacia dei farmaci ad azione antivirale diretta nel trattamento dell’epatite cronica C nella popolazione carceraria italiana

  Roberto Ravasio, Luciano Lucania, Roberto Ranieri, Raquel Dominguez

  103-111

• Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019

  Mariangela Prada, Letizia Rossi, Matteo Mantovani

  89-94

• Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment

  Matteo Ruggeri, Alessandro Signorini, Carlo Drago, Francesco Rosiello, Marco Marchetti

  95-102

• Socioeconomic impact of migraine in Italy: Results of a national survey

  Mihaela Nica, Delia Colombo, Roberto Ravasio, Carla Rognoni

  80-88

• Economic evaluation of low-dose SKA cytokines in patients with rheumatoid arthritis in maintaining low disease activity or remission

  Roberto Ravasio, Alberto Migliore

  67-73

• A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy Analisi di budget impact del biosimilare di pegfilgrastim nel trattamento della neutropenia febbrile in Italia

  Roberto Ravasio, Lorenzo Antonuzzo, Marco Danova, Paolo Pronzato

  4-8

• The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

  Claudio Jommi, Roberto Ravasio

  78-85

• Getting your devices ready for MDR compliance – a clinical approach and orthopaedic device manufacturers’ perspective

  Peter Fennema, Hassan Achakri

  70-75

• Lean Management: organizational innovations in hematological Day-Hospitals Lean Management: innovazioni organizzative nei Day Hospital Ematologici

  Caterina Bianciardi, Jacopo Guercini

  62-69

• Performance indicators for monitoring the integrated care pathway of patients with colorectal cancer: the E.Pic.A. project Performance indicators for colorectal cancer

  Andrea Ricotti, Giovanni Messori Ioli, Mattia Altini, Letizia Bachini, William Balzi, Giovanni Luca Frassineti, Fabrizio Gemmi, Ilaria Massa, Andrea Pierini, Oscar Bertetto, Patrizia Racca

  48-54

• Key performance indicators for monitoring the integrated care pathway in breast cancer: the E.Pic.A. project

  Mattia Altini, William Balzi, Roberta Maltoni, Fabio Falcini, Flavia Foca, Giovanni Messori Ioli, Andrea Ricotti, Oscar Bertetto, Marinella Mistrangelo, Gianni Amunni, Fabrizio Gemmi, Letizia Bachini, Andrea Silenzi, Roberta Pastorino, Andrea Barbara, Andrea Pierini, Ilaria Massa

  31-38

• A Budget impact analysis of adalimumab biosimilar: the Italian context Analisi di budget impact del biosimilare di adalimumab: lo scenario italiano

  Roberto Ravasio, Silvio Mazzi, Maria Esposito, Gionata Fiorino, Alberto Migliore

  16-23